We speculate that patients with ovarian cancer expressing DSG2 may be more susceptible to the oncolytic activity of ONCOS‐102 and other oncolytic AD5/3 vectors than those with EOC without detectable DSG2 expression. This evidence concerns the gene DSG2 and ovarian carcinoma.